Becton, Dickinson and Company (BDX)
| Market Cap | 70.12B |
| Revenue (ttm) | 19.00B |
| Net Income (ttm) | 1.52B |
| Shares Out | 283.90M |
| EPS (ttm) | 5.31 |
| PE Ratio | 46.30 |
| Forward PE | 20.58 |
| Dividend | $3.56 (1.44%) |
| Ex-Dividend Date | Mar 9, 2023 |
| Volume | 294,376 |
| Open | 246.49 |
| Previous Close | 245.17 |
| Day's Range | 244.25 - 247.23 |
| 52-Week Range | 215.90 - 277.29 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 279.48 (+13.16%) |
| Earnings Date | May 4, 2023 |
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devic... [Read more]
Financial Performance
In 2022, BDX's revenue was $18.87 billion, a decrease of -1.36% compared to the previous year's $19.13 billion. Earnings were $1.69 billion, a decrease of -15.63%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for BDX stock is "Buy." The 12-month stock price forecast is $279.48, which is an increase of 13.16% from the latest price.
News
BDX or WST: Which Is the Better Value Stock Right Now?
BDX vs. WST: Which Stock Is the Better Value Option?
2 Unique Dividend Aristocrats to Diversify the Portfolio
Here are two Dividend Aristocrats that are top-rated Zacks stocks at the moment and can offer unique exposure and diversification to investors' portfolios.
BD's (BDX) New FDA Approval to Improve Vaginitis Testing
BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of vaginitis.
BD Receives FDA 510(k) Clearance for First-of-Its-Kind High-Throughput Diagnostic Test for Infectious Vaginitis
BD Vaginal Panel on BD COR™ System Tests for Multiple Common Types of Vaginitis Using Only One Swab, One Test FRANKLIN LAKES, N.J. , March 16, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (...
Healthcare Stocks With at Least 30 Years of Dividend Increases
While it is not the only factor to consider, the annual dividend can solidify whether a stock will benefit you financially. And among the many industry sectors to invest in, healthcare can be one of t...
3 Stocks to Buy for Consistent Dividend Growth
Some of these companies have been around for over 100 years and have seen all imaginable economic environments
Three Reasons to Add BD (BDX) Stock to Your Portfolio Now
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.
BD (BDX) Boosts Molecular Diagnostics Portfolio With New Tests
Recent developments in the Molecular Diagnostics space have been aiding key MedTech players like BD (BDX) to boost their business.
BDX or ALGN: Which Is the Better Value Stock Right Now?
BDX vs. ALGN: Which Stock Is the Better Value Option?
BD to Present at Barclays Global Healthcare Conference
FRANKLIN LAKES, N.J. , March 1, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Barclays G...
BD's (BDX) New FDA Approval to Improve Cervical Cancer Testing
BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of cervical cancer.
The 7 Best Dividend Growth Stocks for Long-Term Investors
When faced with myriad market ambiguities, investors may be well served to target the best dividend growth stocks to buy. In many ways, this investment category represents the best of both worlds.
BD to Present at Cowen 43rd Annual Healthcare Conference
FRANKLIN LAKES, N.J. , Feb. 21, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Cowen 43rd...
BD Onclarity™ HPV Assay Receives FDA Approval for Use with Both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test
Expands Access to BD HPV Test that More Precisely Identifies Patients' Risk for Cervical Cancer FRANKLIN LAKES, N.J. , Feb. 21, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a l...
BD Named as One of America's Best Large Employers
FRANKLIN LAKES, N.J. , Feb. 15, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that the company has been named to America's...
BD's (BDX) Latest Combination Test Receives the FDA's EUA
BD's (BDX) new combination test is likely to significantly aid clinicians in treating patients in the current and future respiratory virus seasons.
BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test
Single Test on BD MAX™ Molecular Diagnostic System Identifies and Differentiates Multiple Respiratory Infectious Diseases FRANKLIN LAKES, N.J. , Feb. 8, 2023 /PRNewswire/ -- BD (Becton, Dickinson and ...
BDX vs. WST: Which Stock Is the Better Value Option?
BDX vs. WST: Which Stock Is the Better Value Option?
BD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery
New BD Rhapsody™ HT Xpress System and Other Innovations to be Unveiled at AGBT, Enhancing an End-To-End Single-Cell Multiomics Offering FRANKLIN LAKES, N.J. , Feb. 3, 2023 /PRNewswire/ -- BD (Becton, ...
BD (BDX) Q1 Earnings and Revenues Beat Estimates, Margins Down
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.
Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates
Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.61% and 0.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BD Reports First Quarter Fiscal 2023 Financial Results
Execution of BD 2025 Strategy Delivering Consistent and Durable Performance Revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis Revenue from base business...
MedTech Stocks' Earnings to Watch on Feb 2: BDX, DGX & CNMD
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how BDX, DGX and CNMD are likely to fare this time.
Should You Buy Becton Dickinson (BDX) Ahead of Earnings?
Becton Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.